It has also been shown that SGLT-2 inhibitors provide significant cardio-renal benefits for specific patients populations, mainly those with HF or chronic kidney disease, even without concomitant DM [18, 19], whereas recent evidence also suggests that GLP-1 receptor agonists might also confer significant cardiovascular risk reduction in patients without DM at baseline, such as those being overweight or obese [20]. The gene discussed is SLC5A2; the disease is hydrops fetalis.